Pfizer has made a major strategic move by agreeing to acquire Metsera in a transaction worth up to $10 billion, beating Novo Nordisk after a tense week-long bidding contest. Announced on November 7, the deal values Metsera at $86.25 per share, with the potential for additional milestone payments.
Metsera’s board chose Pfizer’s offer over Novo Nordisk’s after U.S. regulators flagged antitrust concerns with the rival bid, making Pfizer’s proposal the clearer, lower-risk option. The acquisition gives Pfizer access to Metsera’s promising obesity drug candidates, strengthening its position in the fast-growing obesity therapeutics market.
The merger is expected to close soon after Metsera’s shareholder vote on November 13.
